Navigation Links
Glazer receives grant to study light-activated cancer drugs
Date:1/31/2013

LEXINGTON, Ky. (Jan. 31, 2013) University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

Cisplatin is a common platinum-based cancer drug used in a variety of cancer treatments. But while cisplatin kills cancer cells, it also attacks healthy cells, causing debilitating side effects. Ruthenium is another transition metal and belongs to the same group of the periodic table as iron.

Previously, the Glazer group developed two new ruthenium complexes designed to kill cancer cells while preserving healthy cells. These complexes are inert in the dark, but when activated with light, they become up to 200 times as toxic, and up to three times as potent as cisplatin against tumor cells.

Funded by the American Cancer Society, the new grant will allow Glazer's team to develop improved ruthenium-based compounds and to study their effectiveness. Using the strategy of combining organic ligands as building blocks that assemble around the ruthenium center "core," a large family of compounds with different structures and properties can be rapidly synthesized. This is in marked contrast to approaches using compounds discovered in nature, called natural products, as chemotherapeutics.

Many chemotherapeutics are natural products, but their synthesis is challenging and there are limited chemical modifications that can be made into the molecules. In the ruthenium compounds, the organic components can be easily changed to alter chemical properties and possibly even what types of cells the compounds will enter in the body. The different structures can also potentially prevent the development of drug resistance, as tumors that become resistant to one particular ruthenium drug structure could be vulnerable to another ruthenium compound with a different structure.

The efficacy of the compounds will be tested in different human cancer cell lines and in animal models to determine what cancer types can be treated. The group will also determine the biochemical process by which the compounds kill cells in order to optimize the drugs. The long-term goal of the research is to develop a targeted chemotherapeutic approach with reduced side effects that can be applied to a variety of cancer types.


'/>"/>

Contact: Allison Perry
allison.perry@uky.edu
859-323-2399
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... The Radiology ... Quest Awards . The annual awards, now in their 12th year, are among the ... the winners. , In 2016, the awards were retooled to recognize achievements in both ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... In 2016 ... now estimates that there could be four million Zika-related cases in the Americas within ... with numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... , March 24, 2017 Today ... Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. ... Inc. (NASDAQ: SSH ). These companies are part ... prior gains on Thursday, March 23 rd , 2017, with ... while shares of health care companies in the S&P 500 ...
Breaking Medicine Technology: